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Background. The aim of this study was to evaluate the role and impact of EUS in the management of critically ill patients. Methods.
We retrospectively identified all patients at our institution over a 68-month period in whom bedside inpatient EUS was performed.
EUS was considered to have a significant impact if a new diagnosis was established and/or the findings altered subsequent clinical
management. Results. Fifteen patients (9 male; mean age 58±15 years) underwent bedside EUS without complications. EUS-FNA
(median 4 passes; range 2–7) performed in 12 (80%) demonstrated a malignant mediastinal mass/lymph node (5), pancreatic
abscess (1), excluded a pelvic abscess (1), established enlarged gastric folds as benign (1) and excluded malignancy in enlarged
mediastinal (1) and porta hepatis adenopathy (1). In two patients, EUS-FNA failed to diagnose mediastinal histoplasmosis (1)
and a hemorrhagic pancreatic pseudocyst (1). In three diagnostic exams without FNA, EUS correctly excluded choledocholithaisis
(n = 1) and cholangiocarcinoma (1), and found gastric varices successfully thrombosed after previous cyanoacrylate injection (1).
EUS was considered to have an impact in 13/15 (87%) patients. Conclusions. In this series, bedside EUS in critically ill patients was
technically feasible, safe and had a major impact on the majority of patients.
1. Introduction
Endoscopic ultrasonography (EUS) is an established modal-
ity for the diagnosis of esophagogastric, mediastinal, pancre-
atobiliary, and pelvic lesions. However, it is mainly used for
elective procedures in outpatients and occasionally inpatients
who are at low risk for complications from moderate or
deep sedation. While diagnostic and therapeutic endoscopy
procedures such as PEG placement or evaluation of GI
bleeding are routinely performed at the bedside in intensive
care units (ICUs), the use of EUS for this indication has been
described in only two small case series [1, 2]. In this study,
we report a single center experience of the indications and
impact of bedside EUS on the care of ICU patients.
2. Methods
This study was approved by the Institutional Review Board
at Clarian Health Partners/Indiana University Hospital. Our
prospectively updated endoscopy database was queried to
identify all patients who underwent a bedside EUS procedure
in an ICU at our hospital between January 2004 and August
2009.
Patients in this cohort were deemed by their treating
physicians to require ICU care and also an EUS procedure for
evaluation of various pancreaticobiliary, thoracic, or pelvic
disorders. To complete these procedures, patients were not
deemed stable for transport to our endoscopy unit and
therefore required a bedside procedure.
Sedation for these procedures varied depending on the
presence or absence of previous endotracheal intubation. If
the patient was intubated, intravenous sedatives or narcotics
already being administered to the patient were given for
the procedure either by intermittent boluses or a temporary
increase in the maintenance infusion rate. Alternatively,
intermittent boluses of propofol were used. If the patient
was not intubated, then sedation was accomplished by
intermittent boluses of benzodiazepines and/or opioids.
Appropriate cardiorespiratory monitoring was used for all
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patients. Informed consent was obtained from the patient,
patients’ relative or power of attorney in all cases.
All procedures were performed by or under the super-
vision of one of five experienced attending endosonogra-
phers. If a radial echoendoscope was required, examina-
tion was initiated with an Olympus GF-UE160-AL5 radial
echoendoscope (Olympus America, Inc., Center Valley, PA,
USA). Curvilinear array endosonography was performed
using an Olympus GF-UC30P or Olympus GF-UC140P-AL5
(Olympus America, Inc., Center Valley, PA, USA) echoen-
doscope. EUS-FNA was performed at the discretion of the
endosonographer and if performed was obtained using a
19 or a 22-gauge EUSN-1, EUSN-2, EUSN-3, or Echotip
Ultra needle (Cook Medical Inc., Winston-Salem, NC,
USA) or EZ-Shot needle (Olympus America, Inc., Center
Valley, PA, USA). Doppler examination was used to ensure
the absence of intervening vascular structures along the
anticipated needle path. Depending on the amount of
blood anticipated during tissue sampling, full, partial, or no
suction was applied. When a cytopathologist and portable
microscope were available on site for preliminary diagnostic
interpretations and assessment of specimen adequacy, FNA
samples were expressed onto a glass slide and two smear
preparations were made. One slide preparation was air-dried
and stained with a modified Giemsa stain for on-site review,
while the other slide was alcohol-fixed and stained by the
Papanicolaou method. In the absence of on-site pathology
review, samples were only alcohol-fixed for future staining
and interpretation. EUS-FNA was repeated until a definitive
diagnosis was made or the endosonographers felt that further
sampling would not likely increase yield. Additional FNA
passes were made when either (1) a cellblock preparation was
potentially required for immunostains or (2) microbiology
stains and cultures were required for potential sites of infec-
tions. Definitive cytopathologic diagnoses were given only
after complete staining and subsequent final interpretation
was provided. Hospital records and endoscopy charts were
reviewed after the procedure to assess for any short-term
complications and clinical followup.
For study purposes, EUS was considered to have a sig-
nificant impact if a new diagnosis was established and/or
the findings altered subsequent management. EUS was not
considered to have an impact if a diagnosis was incorrectly
interpreted or missed. When available, the final clinical diag-
nosis for each patient was made by autopsy or surgery. In
the absence of either, the results of EUS-FNA and clinical
followup were used.
3. Results
3.1. Study Population. Fifteen patients (9 male; mean age:
58 ± 15 years) were included. Twelve were from American
Society of Anesthesiology (ASA) class III and three were
from ASA class IV. Eight (53%) were under mechanical
ventilation during EUS. Bed location for these 15 patients
included Medical ICU in nine, Surgical ICU in three, Organ
Transplant ICU in two, and Neurosurgical ICU in one.
Reasons for ICU admission were respiratory failure in seven,
severe sepsis in three, severe pancreatitis in two, cardiac arrest
in one, liver failure in one, and gastrointestinal bleeding
in one. Past history of severe underlying disorder in seven
patients included alcoholic cirrhosis in two, retroperitoneal
fibrosis in one, renal and pancreas transplant in one, renal
transplant in one, Hodgkin’s disease in one, and bladder
cancer in one.
3.2. EUS Findings. Indications for EUS were mediastinal
mass or adenopathy (n = 7), suspected pancreas mass or
abscess (n = 3), evaluation of suspected choledocholithiasis
or biliary obstruction (n = 2), suspected gastric mass (n =
1), gastric variceal bleeding (n = 1), and suspected pelvic
abscess (n = 1).
Bedside EUS was technically successful and completed
in all patients without complications. Twelve (80%) patients
underwent EUS-FNA (median 4 passes; range 2–7) and
a cytopathologist was available on site for preliminary
interpretations in 8 of 12 (66.7%). The findings and results
of the EUS exams are summarized in Table 1.
EUS-FNA provided an initial diagnosis of a malignant
mediastinal mass/lymph node in five including nonsmall cell
lung cancer (NSCLC) in two, small cell lung cancer (SCLC) in
one, metastatic adenocarcinoma in one, and non-Hodgkin’s
lymphoma (NHL) in one. Additionally, EUS-FNA diagnosed
a pancreas abscess (n = 1), excluded a pelvic abscess (n =
1), and established enlarged gastric folds (n = 1) and
lymph nodes in the mediastinum (n = 1) and portahepatis
region (n = 1) as benign. In the three diagnostic exams
without FNA, EUS excluded both choledocholithaisis (n =
1) and a extrahepatic bile duct tumor (n = 1), and found
gastric varices were successfully thrombosed after previous
cyanoacrylate injection (n = 1).
EUS failed to establish a correct diagnosis in two patients.
In one (patient 2, Table 1), EUS-FNA of a heterogeneous
retroperitoneal mass was reported as suspicious for lym-
phoma, but autopsy showed the lesion was a hemorrhagic
pancreatic pseudocyst in the setting of systemic amyloidosis.
In the second case (patient 14, Table 1), EUS-FNA of a
mediastinal mass incorrectly revealed necrosis but was later
confirmed after surgery as histoplasmosis. EUS was therefore
considered to have an impact in 13 of 15 (87%) patients,
including 10 of 12 (83%)who had EUS-FNA and all the three
(100%) who underwent diagnostic EUS alone.
Six (40%) patients died during their ICU admission and
the remaining nine were discharged. Five of these died within
three months of hospitalization while four remained alive a
median 321 days (range: 209–706 days) after discharge. No
short-term complications were noted during or immediately
after EUS.
4. Discussion
There are limited data previously published in two small
series that describe the utility of bedside EUS in critically
ill patients. Fritscher-Ravens et al. [1] reported the bedside
use of EUSFNA in three patients to diagnose a mediastinal
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abscess following tracheotomy (n = 1), relieve pressure
from a paratracheal hematoma compressing the right main
bronchus (n = 1) and diagnose lung cancer in a patient
awaiting cardiac transplantation (n = 1). The authors
concluded that bedside EUS-FNA was feasible and could
oﬀer an alternative in life-threatening situations.
Varadarajulu et al. [2] recently described the use and
positive clinical impact of EUS in six patients to establish a
diagnosis of choledocholithiasis (n = 1), mediastinal abscess
(n = 1), and pancreatic abscess (n = 1) in 3 patients and
its use in two other patients to rule out the presence of
choledocholithiasis (n = 1) and a pancreatic pseudocyst (n =
1). The authors also reported the successful use of beside
EUS-guided transmural drainage of a pancreatic pseudocyst
and mediastinal abscess.
In the current series, we found that bedside EUS had a
clinical impact in 13 of 15 critically ill patients evaluated. A
new diagnosis was established in 6 cases and precluded the
need for further studies or intervention in seven others. We
found that the most common clinical impact made by EUS
was providing a tissue diagnosis of malignancy. However,
as the other two reported series [1, 2] found, diagnostic
EUS provided important clinical information as well. One
of our patients underwent transrectal EUS during which
sampling of a pelvic fluid collection correctly excluded a
suspected abscess. To our knowledge, this case represents the
first description of bedside rectal EUS.
The current study represents the largest series to date
detailing the use of bedside EUS and confirms its utility and
impact in this patient population. Nevertheless our study is
limited by its retrospective design and limited followup in
some patients. Further prospective studies involving larger
numbers of patients are needed to further define the role of
EUS in critically ill patients.
In conclusion, bedside EUS in ICU patients is safe and
feasible. In the current series, it had a significant impact
on the management of the majority of patients evaluated.
Therefore, endosonographers should consider using EUS in
ICU patients when clinically indicated. Given the expanding
field of EUS, we postulate that therapeutic procedures such as
pancreatic necrosectomy [3–5] and cholecystoenterostomy
[6] could be performed at the bedside in these patients
as an alternative to surgical or interventional radiology
procedures.
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